» Articles » PMID: 33760392

Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort

Overview
Publisher Wiley
Specialty Rheumatology
Date 2021 Mar 24
PMID 33760392
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in systemic sclerosis (SSc). This study was undertaken to assess predictive accuracies of the DETECT algorithm and the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines in SSc patients who underwent right-sided heart catheterization (RHC) for pulmonary hypertension (PH) evaluation.

Methods: Patients with SSc who had diagnostic RHC, had no PH or had PAH, and had available data on variables to allow application of the DETECT and 2015 ESC/ERS guidelines were included for analysis. PH classification was based on hemodynamics using the 2018 revised criteria and extent of lung fibrosis shown on high-resolution computed tomography. Sensitivity and predictive accuracies of the DETECT algorithm and 2015 ESC/ERS guidelines were calculated, including analysis of subjects with a diffusing capacity for carbon monoxide (DLco) of ≥60% predicted.

Results: Sixty-eight patients with SSc had RHC, of whom 58 had no PH and 10 had PAH. The mean age was 60.0 years, and 58.8% had limited cutaneous SSc. The DETECT algorithm had a sensitivity of 1.00 (95% confidence interval [95% CI] 0.69-1.00) and a negative predictive value (NPV) of 1.00 (95% CI 0.80-1.00), whereas the 2015 ESC/ERS guidelines had a sensitivity of 0.80 (95% CI 0.44-0.97) and an NPV of 0.94 (95% CI 0.81-0.99). In patients with a DLco of ≥60% (n = 27), the DETECT algorithm had a sensitivity of 1.00 (95% CI 0.29-1.00) and an NPV of 1.00 (95% CI 0.59-1.00), whereas the 2015 ESC/ERS guidelines had a sensitivity of 0.67 (95% CI 0.09-0.99) and an NPV of 0.94 (95% CI 0.71-1.00).

Conclusion: The DETECT algorithm has high sensitivity and NPV for diagnosis of PAH, including among individuals with a DLco of ≥60%.

Citing Articles

Extracellular Vesicles as a Potential Biomarker of Pulmonary Arterial Hypertension in Systemic Sclerosis.

Tonello S, DOnghia D, Di Ruscio A, Mora S, Vincenzi F, Caria G Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006072 PMC: 11859480. DOI: 10.3390/ph18020259.


Predictive Value of the DETECT Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis: Findings from an Italian Observational Study.

Stano S, Iannone C, DAgostino C, Pellico M, Urso L, Papa N J Clin Med. 2025; 14(2.

PMID: 39860644 PMC: 11765971. DOI: 10.3390/jcm14020638.


Multimodal Screening for Pulmonary Arterial Hypertension in Systemic Scleroderma: Current Methods and Future Directions.

Dragoi I, Rezus C, Burlui A, Bratoiu I, Rezus E Medicina (Kaunas). 2025; 61(1).

PMID: 39859001 PMC: 11766816. DOI: 10.3390/medicina61010019.


Smartphone Apps for Pulmonary Hypertension: Systematic Search and Content Evaluation.

Baez Gutierrez N, Rodriguez Ramallo H, Mendoza-Zambrano E, Brown Arreola B, Santos Ramos B, Abdel-Kader Martin L JMIR Mhealth Uhealth. 2024; 12:e57289.

PMID: 39476376 PMC: 11540248. DOI: 10.2196/57289.


Biomarkers reflecting the pathogenesis, clinical manifestations, and guide therapeutic approach in systemic sclerosis: a narrative review.

Bazso A, Szodoray P, Shoenfeld Y, Kiss E Clin Rheumatol. 2024; 43(10):3055-3072.

PMID: 39210206 PMC: 11442557. DOI: 10.1007/s10067-024-07123-y.


References
1.
Guillen-Del Castillo A, Callejas-Moraga E, Garcia G, Rodriguez-Palomares J, Roman A, Berastegui C . High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. Arthritis Res Ther. 2017; 19(1):135. PMC: 5471690. DOI: 10.1186/s13075-017-1327-8. View

2.
Denton C, Khanna D . Systemic sclerosis. Lancet. 2017; 390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. View

3.
Schwaiger J, Khanna D, Coghlan J . Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev. 2013; 22(130):515-25. PMC: 9639190. DOI: 10.1183/09059180.00006013. View

4.
Khanna D, Zhao C, Saggar R, Mathai S, Chung L, Coghlan J . Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. Arthritis Rheumatol. 2021; 73(5):837-847. PMC: 8251834. DOI: 10.1002/art.41669. View

5.
Coghlan J, Denton C, Grunig E, Bonderman D, Distler O, Khanna D . Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2013; 73(7):1340-9. PMC: 4078756. DOI: 10.1136/annrheumdis-2013-203301. View